Early clinical experience with bleomycin in the United Kingdom in series of 105 patients.
The results of treating a series of 105 patients (79 with advanced squamous cell carcinoma, 21 with advanced lymphoma, and 5 with miscellaneous tumours) with bleomycin are described. The drug was usually given as a single agent. Four patients with squamous cell carcinoma showed complete regression and there was partial regression in 25. Side effects were frequent, particularly skin changes and stomatitis; death from pneumonitis occurred in one patient.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000150:complications; D011859:Radiography; D013280:Stomatitis / Q000139:chemically induced; D014062:Tongue Neoplasms / Q000188:drug therapy; D006113:United Kingdom
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin